Skip to content
  • CONTACT US
  • CAREERS
  • Share
Allogene Logo
  • PIPELINE
    • AlloCAR T™ PRODUCT PIPELINE
    • THE ALPHA3 TRIAL
    • DATABRIEF
    • EXPANDED ACCESS
  • SCIENCE
    • NEXT REVOLUTION IN CELL THERAPY
    • PLATFORM FOR TOMORROW
    • ON-DEMAND AVAILABILITY
    • SCIENTIFIC PUBLICATIONS
  • ABOUT US
    • AT A GLANCE
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORS
    • PARTNERS
    • CORPORATE RESPONSIBILITY
  • NEWS CENTER
    • PRESS RELEASES
    • EVENTS
    • PERSPECTIVES
    • SOCIAL MEDIA
    • COMMUNITY GUIDELINES
  • INVESTORS
    • IR OVERVIEW
    • NEWS & EVENTS
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • DOCUMENTS & CHARTERS
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIALS & FILINGS
      • SEC FILINGS
    • RESOURCES
      • INVESTOR FAQs
      • EMAIL ALERTS
      • IR INQUIRY
  • PIPELINE
    • AlloCAR T™ PRODUCT PIPELINE
    • THE ALPHA3 TRIAL
    • DATABRIEF
    • EXPANDED ACCESS
  • SCIENCE
    • NEXT REVOLUTION IN CELL THERAPY
    • PLATFORM FOR TOMORROW
    • ON-DEMAND AVAILABILITY
    • SCIENTIFIC PUBLICATIONS
  • ABOUT US
    • AT A GLANCE
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORS
    • PARTNERS
    • CORPORATE RESPONSIBILITY
  • NEWS CENTER
    • PRESS RELEASES
    • EVENTS
    • PERSPECTIVES
    • SOCIAL MEDIA
    • COMMUNITY GUIDELINES
  • INVESTORS
    • IR OVERVIEW
    • NEWS & EVENTS
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • DOCUMENTS & CHARTERS
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIALS & FILINGS
      • SEC FILINGS
    • RESOURCES
      • INVESTOR FAQs
      • EMAIL ALERTS
      • IR INQUIRY
Read more about the article Toward “Off-the-Shelf” Allogeneic CAR T Cells

Toward “Off-the-Shelf” Allogeneic CAR T Cells

  • Post author:andrewkaretas
  • Post published:April 18, 2020
  • Post category:PLATFORM/Scientific Publications

Continue ReadingToward “Off-the-Shelf” Allogeneic CAR T Cells
Read more about the article American Society of Hematology (ASH) Dec. 2019 – Preclinical Evaluation of ALLO-819, Targeting FLT3, in Acute Myeloid Leukemia

American Society of Hematology (ASH) Dec. 2019 – Preclinical Evaluation of ALLO-819, Targeting FLT3, in Acute Myeloid Leukemia

  • Post author:andrewkaretas
  • Post published:December 18, 2019
  • Post category:FLT3/Scientific Publications

Continue ReadingAmerican Society of Hematology (ASH) Dec. 2019 – Preclinical Evaluation of ALLO-819, Targeting FLT3, in Acute Myeloid Leukemia
Read more about the article American Society of Hematology (ASH) Dec. 2019 – Allogeneic Anti-BCMA CAR T Cells Show Tumor Specific Killing Against Primary Multiple Myeloma Cells

American Society of Hematology (ASH) Dec. 2019 – Allogeneic Anti-BCMA CAR T Cells Show Tumor Specific Killing Against Primary Multiple Myeloma Cells

  • Post author:andrewkaretas
  • Post published:December 18, 2019
  • Post category:BCMA/Scientific Publications

Continue ReadingAmerican Society of Hematology (ASH) Dec. 2019 – Allogeneic Anti-BCMA CAR T Cells Show Tumor Specific Killing Against Primary Multiple Myeloma Cells
Read more about the article American Association for Cancer Research (AACR) April 2019 – AlloCAR T™ Targeting CD70 For RCC

American Association for Cancer Research (AACR) April 2019 – AlloCAR T™ Targeting CD70 For RCC

  • Post author:andrewkaretas
  • Post published:April 18, 2019
  • Post category:CD70/Scientific Publications

Continue ReadingAmerican Association for Cancer Research (AACR) April 2019 – AlloCAR T™ Targeting CD70 For RCC
Read more about the article American Society of Hematology (ASH) Dec. 2018 – ALLO-819, An Allogeneic FLT3 CAR T Therapy Possessing An Off-Switch for the Treatment of Acute Myeloid Leukemia

American Society of Hematology (ASH) Dec. 2018 – ALLO-819, An Allogeneic FLT3 CAR T Therapy Possessing An Off-Switch for the Treatment of Acute Myeloid Leukemia

  • Post author:andrewkaretas
  • Post published:December 18, 2018
  • Post category:FLT3/Scientific Publications

Continue ReadingAmerican Society of Hematology (ASH) Dec. 2018 – ALLO-819, An Allogeneic FLT3 CAR T Therapy Possessing An Off-Switch for the Treatment of Acute Myeloid Leukemia
Read more about the article American Society of Hematology (ASH) Dec. 2018 — UCART19 PALL and CALM Studies

American Society of Hematology (ASH) Dec. 2018 — UCART19 PALL and CALM Studies

  • Post author:andrewkaretas
  • Post published:December 1, 2018
  • Post category:CD19/Scientific Publications

Continue ReadingAmerican Society of Hematology (ASH) Dec. 2018 — UCART19 PALL and CALM Studies
Read more about the article A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies Valton J, Guyot V, Boldajipour B, et al.

A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies Valton J, Guyot V, Boldajipour B, et al.

  • Post author:andrewkaretas
  • Post published:June 18, 2018
  • Post category:PLATFORM/Scientific Publications

Scientific Reports

Continue ReadingA Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies Valton J, Guyot V, Boldajipour B, et al.
Read more about the article American Society of Gene and Cell Therapy (ASGCT) May 2018 – Development of an In Vitro Cynomolgus Macaque Allogeneic CAR T Cell Platform

American Society of Gene and Cell Therapy (ASGCT) May 2018 – Development of an In Vitro Cynomolgus Macaque Allogeneic CAR T Cell Platform

  • Post author:andrewkaretas
  • Post published:May 18, 2018
  • Post category:PLATFORM/Scientific Publications

Continue ReadingAmerican Society of Gene and Cell Therapy (ASGCT) May 2018 – Development of an In Vitro Cynomolgus Macaque Allogeneic CAR T Cell Platform
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
Allogene

CONNECT

210 E. Grand Avenue
South San Francisco, CA 94080

View Map / Contact Us

LinkedIn
X (Twitter)
  • PIPELINE
    • AlloCAR T™ Product Pipeline
    • THE ALPHA3 TRIAL
    • DATABRIEF
    • Expanded Access
  • SCIENCE
    • Next Revolution in Cell Therapy
    • Platform for Tomorrow
    • On-Demand Availability
    • Scientific Publications
  • ABOUT US
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Corporate Responsibility
  • NEWS CENTER
    • Press Releases
    • Events
    • Perspectives
    • Social Media
    • Community Guidelines
  • INVESTORS
    • Press Releases
    • Events
    • Presentations
    • Stock Information
    • Stock Quote & Chart
    • Historical Price Look Up
    • Investment Calculator
    • Corporate Governance
    • Documents & Charters
  • INVESTORS
    • Board of Directors
    • Management
    • Committee Composition
    • SEC Filings
    • Resources
    • Investor FAQs
    • Email Alerts
    • IR Inquiry
Facebook
X (Twitter)
LinkedIn
E-Mail
Tumblr
Reddit
WhatsApp
Telegram
Allogene

CONNECT

210 E. Grand Avenue
South San Francisco, CA 94080

View Map / Contact Us

LinkedIn
X (Twitter)
  • PIPELINE
    • AlloCAR T™ Product Pipeline
    • THE ALPHA3 TRIAL
    • DATABRIEF
    • Expanded Access
  • SCIENCE
    • Next Revolution in Cell Therapy
    • Platform for Tomorrow
    • On-Demand Availability
    • Scientific Publications
  • ABOUT US
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Corporate Responsibility
  • NEWS CENTER
    • Press Releases
    • Events
    • Perspectives
    • Social Media
    • Community Guidelines
  • INVESTORS
    • Press Releases
    • Events
    • Presentations
    • Stock Information
    • Stock Quote & Chart
    • Historical Price Look Up
    • Investment Calculator
    • Corporate Governance
    • Documents & Charters
  • INVESTORS
    • Board of Directors
    • Management
    • Committee Composition
    • SEC Filings
    • Resources
    • Investor FAQs
    • Email Alerts
    • IR Inquiry

©2024 ALLOGENE THERAPEUTICS

TERMS OF USE

COOKIE SETTINGS

PRIVACY NOTICE

©2024 ALLOGENE THERAPEUTICS

TERMS OF USE

COOKIE SETTINGS

PRIVACY NOTICE